Peer-reviewed research on wildfire smoke exposure and lung disease, translated by our student research team.
Pulmonary fibrosis slowly scars and stiffens the lungs. Here's how the disease works, why treatment options stayed so limited for so long, and what the first new IPF drug in over a decade changes.
COPD ranks among the top three causes of death worldwide, yet its early symptoms are easy to mistake for aging or a lingering cold. A look at its causes, diagnosis, treatment, and the research pushing past symptom management.
The asthma that shows up in a wheezing toddler often looks nothing like the asthma that develops at 45. How triggers, diagnosis, and long-term outcomes differ between childhood and adult onset.
For decades, cystic fibrosis care meant managing symptoms. CFTR modulators target the faulty protein behind the disease itself, and they've changed the outlook for most patients.
Wildland firefighters inhale PM2.5, VOCs, and other carcinogenic compounds with little to no respiratory protection. Here's what that exposure does to lung tissue, and why the WHO classifies firefighting as a cancer-causing occupation.
Standard lung-function tests often miss smoke-related damage until it's advanced. Researchers are turning to measurable biomarkers in blood, breath, and saliva to flag injury years before symptoms appear.
Start one at your school, fund the next delivery, or bring Project Pulmonary to your department.
Project Pulmonary is a 501(c)(3). Every gift is tax-deductible.
